Total Payments
$712,615
2024 Payments
$130,748
Companies
27
Transactions
1,257
Medicare Patients
12,096
Medicare Billing
$806,481
Payment Breakdown by Category
Other$633,042 (88.8%)
Travel$38,367 (5.4%)
Food & Beverage$25,032 (3.5%)
Consulting$15,680 (2.2%)
Education$494.22 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $633,042 | 259 | 88.8% |
| Travel and Lodging | $38,367 | 208 | 5.4% |
| Food and Beverage | $25,032 | 772 | 3.5% |
| Consulting Fee | $15,680 | 7 | 2.2% |
| Education | $494.22 | 11 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $387,873 | 586 | $0 (2024) |
| Dermavant Sciences, Inc. | $97,388 | 95 | $0 (2024) |
| Amgen Inc. | $91,387 | 149 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $39,370 | 57 | $0 (2024) |
| GENZYME CORPORATION | $37,316 | 60 | $0 (2024) |
| Celgene Corporation | $25,569 | 83 | $0 (2019) |
| Incyte Corporation | $25,134 | 30 | $0 (2024) |
| Galderma Laboratories, L.P. | $5,549 | 30 | $0 (2024) |
| Janssen Biotech, Inc. | $1,004 | 53 | $0 (2024) |
| PFIZER INC. | $479.74 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $130,748 | 173 | Dermavant Sciences, Inc. ($42,166) |
| 2023 | $128,189 | 202 | Dermavant Sciences, Inc. ($43,372) |
| 2022 | $121,863 | 177 | ABBVIE INC. ($79,580) |
| 2021 | $69,926 | 136 | Amgen Inc. ($35,101) |
| 2020 | $28,482 | 91 | AbbVie Inc. ($11,734) |
| 2019 | $106,685 | 194 | AbbVie, Inc. ($80,702) |
| 2018 | $50,273 | 146 | AbbVie, Inc. ($49,147) |
| 2017 | $76,450 | 138 | AbbVie, Inc. ($75,800) |
All Payment Transactions
1,257 individual payment records from CMS Open Payments — Page 1 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $10.12 | General |
| Category: Immunology | ||||||
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: DERMATOLOGY | ||||||
| 12/10/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $7.18 | General |
| Category: Dermatology | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,004.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $5.66 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $7.28 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/19/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $154.10 | General |
| Category: Inflammation | ||||||
| 11/19/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | Cash or cash equivalent | $19.07 | General |
| Category: Inflammation | ||||||
| 11/19/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: Inflammation | ||||||
| 11/19/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: Inflammation | ||||||
| 11/14/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Travel and Lodging | In-kind items and services | $1,415.50 | General |
| Category: DERMATOLOGY | ||||||
| 11/14/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $107.32 | General |
| Category: DERMATOLOGY | ||||||
| 11/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: Immunology | ||||||
| 11/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,678.00 | General |
| Category: Immunology | ||||||
| 11/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $1,074.00 | General |
| Category: Immunology | ||||||
| 11/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Inflammation | ||||||
| 11/11/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: Inflammation | ||||||
| 11/08/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $300.11 | General |
| Category: Inflammation | ||||||
| 11/08/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $88.44 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,856 | 4,380 | $426,473 | $188,286 |
| 2022 | 21 | 3,135 | 4,732 | $473,015 | $217,184 |
| 2021 | 19 | 2,933 | 4,998 | $434,677 | $196,030 |
| 2020 | 22 | 3,172 | 5,236 | $506,669 | $204,980 |
Total Patients
12,096
Total Services
19,346
Medicare Billing
$806,481
Procedure Codes
82
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 748 | 875 | $99,718 | $49,863 | 50.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 641 | 765 | $83,385 | $30,177 | 36.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 238 | 350 | $60,900 | $29,104 | 47.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 255 | 282 | $40,326 | $19,427 | 48.2% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 51 | 52 | $21,580 | $11,543 | 53.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 170 | 170 | $29,750 | $11,428 | 38.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 437 | 1,555 | $21,770 | $7,138 | 32.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 53 | 53 | $14,204 | $5,774 | 40.7% |
| 12052 | Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | Office | 2023 | 17 | 17 | $7,344 | $3,719 | 50.6% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 25 | 27 | $7,560 | $3,503 | 46.3% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 26 | 26 | $9,750 | $2,844 | 29.2% |
| 12042 | Intermediate repair of wound of neck, hands, feet, or genitals, 2.6-7.5 cm | Office | 2023 | 11 | 11 | $4,345 | $2,486 | 57.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 70 | 73 | $5,110 | $2,390 | 46.8% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 19 | 19 | $4,560 | $2,182 | 47.8% |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | Office | 2023 | 12 | 13 | $3,406 | $1,770 | 52.0% |
| 96450 | Administration of chemotherapy into fluid-filled space between the tissue that cover the brain and spinal cord | Office | 2023 | 12 | 13 | $3,081 | $1,633 | 53.0% |
| 11623 | Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 2.1-3.0 cm | Office | 2023 | 12 | 12 | $4,860 | $1,470 | 30.3% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 31 | 38 | $2,926 | $1,204 | 41.1% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 15 | 15 | $1,800 | $607.09 | 33.7% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 13 | 14 | $98.00 | $24.11 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 732 | 829 | $94,506 | $50,287 | 53.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 691 | 808 | $88,072 | $33,205 | 37.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 257 | 370 | $64,380 | $33,024 | 51.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 292 | 320 | $45,760 | $22,959 | 50.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 230 | 230 | $40,250 | $15,810 | 39.3% |
About Dr. Andrew Lee, M.D
Dr. Andrew Lee, M.D is a Dermatology healthcare provider based in Elkin, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1518154889.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Lee, M.D has received a total of $712,615 in payments from pharmaceutical and medical device companies, with $130,748 received in 2024. These payments were reported across 1,257 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($633,042).
As a Medicare-enrolled provider, Lee has provided services to 12,096 Medicare beneficiaries, totaling 19,346 services with total Medicare billing of $806,481. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Elkin, NC
- Active Since 10/01/2007
- Last Updated 03/29/2011
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1518154889
Products in Payments
- Humira (Biological) $128,255
- Otezla (Drug) $113,601
- SKYRIZI (Biological) $103,837
- VTAMA (Drug) $97,388
- DUPIXENT (Biological) $76,280
- RINVOQ (Biological) $69,148
- OPZELURA (Drug) $25,134
- Skyrizi (Biological) $11,335
- HUMIRA (Biological) $7,706
- AKLIEF (Drug) $5,268
- TREMFYA (Drug) $680.60
- EUCRISA (Drug) $479.74
- DUPIXENT (Drug) $347.08
- ENSTILAR (Drug) $240.43
- Tremfya (Drug) $191.87
- TALTZ (Drug) $185.86
- ADBRY (Biological) $142.85
- REMICADE (Biological) $114.65
- DUOBRII (Drug) $85.01
- DORYX (Drug) $82.56
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.